Fluoroquinolones and G6PD Deficiency
Fluoroquinolones can be used safely in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as there is no solid evidence contraindicating their use at normal therapeutic doses.
Evidence-Based Safety Profile
The most comprehensive systematic review found no solid evidence to prohibit fluoroquinolone use in G6PD-deficient patients 1. After thorough literature review, only seven medications had sufficient evidence for prohibition in G6PD deficiency: dapsone, methylthioninium chloride, nitrofurantoin, phenazopyridine, primaquine, rasburicase, and tolonium chloride—notably, fluoroquinolones are not on this list 1.
Clinical Evidence Supporting Safety
Real-world data from hematologic patients: A retrospective analysis of 242 patients (59 with G6PD deficiency) receiving 628 intensive chemotherapy courses with fluoroquinolone prophylaxis showed zero episodes of acute hemolytic anemia in the entire cohort, including all G6PD-deficient patients 2.
Limited case reports: Despite fluoroquinolones being classically cited as problematic, literature review reveals only a few clearly documented observations of hemolysis, with most cases likely representing infection-related hemolytic episodes rather than drug-induced events 3.
Updated pharmacogenetic guidelines: The 2023 Clinical Pharmacogenetics Implementation Consortium guideline classifies medications by risk level for G6PD deficiency but does not list fluoroquinolones among high-risk agents requiring avoidance 4.
Clinical Context and Caveats
The confusion stems from historical misattribution: Many compounds have been wrongly cited as causing hemolysis because they were administered during infection-related hemolytic episodes, not because the drug itself caused hemolysis 1. This is particularly relevant for fluoroquinolones, which are often prescribed during acute infections—the very trigger that can independently cause hemolysis in G6PD-deficient patients.
Guideline recommendations acknowledge this: HIV treatment guidelines specifically identify dapsone, primaquine, and sulfonamides as the oxidant drugs requiring G6PD screening—fluoroquinolones are conspicuously absent from this list 5.
Practical Approach
- No G6PD screening required before prescribing fluoroquinolones for standard indications 1
- Standard dosing applies without modification for G6PD status 1
- Monitor for hemolysis as you would with any patient during acute infection, recognizing that infection itself (not the antibiotic) is the more likely trigger in G6PD-deficient patients 2
The evidence clearly demonstrates that fluoroquinolones belong in the category of medications where no evidence contraindicates their use in G6PD-deficient patients at normal therapeutic doses 1.